CommercialDocumentationMedium impact
08.01.10k, Octreotide Acetate (Sandostatin® LAR Depot)
Independence Blue Cross·Endocrinology, Gastroenterology, Oncology +1 more·Pharmacy
Effective date
Aug 18, 2025
We identified it
Jun 19, 2026
Summary
Policy 08.01.10k updates medical necessity criteria and medical coding requirements for Octreotide Acetate (Sandostatin® LAR Depot). The billing team must review updated coverage rules and ensure claims comply with new medical necessity documentation standards and coding guidelines effective immediately.
Action Required
By August 18, 2025: Billing team must obtain and review the full policy text from https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=08&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-08-01-10k to identify specific medical necessity criteria and coding changes. Update billing system rules, prior authorization workflows, and provider documentation templates accordingly. Providers must ensure all Octreotide Acetate claims include required medical necessity documentation. Claims submitted without compliance to new criteria will be denied.